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Abstract
Introduction: Sinus bradycardia has been reported after administration of pulse dose steroids, although most cases
have occurred in children and are asymptomatic. We report a case of acute symptomatic sinus bradycardia due to
pulse dose steroids in a woman with multiple sclerosis. Interestingly, this patient also suffered from inappropriate
sinus tachycardia due to autonomic involvement of multiple sclerosis.
Case presentation: A 48-year-old Caucasian woman with multiple sclerosis and chronic palpitations due to
inappropriate sinus tachycardia was prescribed a 5-day course of intravenous methylprednisolone for treatment of
an acute flare. Immediately following the fourth dose of intravenous methylprednisolone, she developed dyspnea,
chest heaviness, and lightheadedness. She was referred to the emergency department where an electrocardiogram
showed marked sinus bradycardia (40 beats per minute). Initial laboratory test results, including a complete blood
count, basic metabolic profile and cardiac biomarkers, were normal. She was admitted for observation on telemetry
monitoring. Her heart rate gradually increased and her symptoms resolved. Her outpatient dose of atenolol, taken
for symptomatic inappropriate sinus tachycardia, was resumed.
Conclusions: Our patient’s acute symptoms were attributed to symptomatic sinus bradycardia due to pulse dose
steroid treatment. Although several theories have been suggested to explain this phenomenon, the exact mechanism
still remains unknown. It does not warrant any specific treatment, as it is a self-limiting side effect that resolves after
discontinuing steroid infusion. Young patients who are free of any active cardiac conditions can safely be administered
pulse dose steroids without monitoring. However, older patients with active cardiac conditions should have heart rate
and blood pressure monitoring during infusion. Our patient also suffered from inappropriate sinus tachycardia, a
manifestation of autonomic involvement of multiple sclerosis that has not been previously described. This case has
implications for the pathogenesis and treatment of dysautonomia in patients with multiple sclerosis.
Keywords: Sinus Bradycardia, Intravenous Methylprednisolone, Pulse Steroid Therapy, Multiple Sclerosis, Inappropriate
sinus tachycardia.
Introduction
Multiple sclerosis (MS) is an autoimmune demyelinating
disease of the central nervous system that frequently
manifests with a waxing and waning course, character-
ized by lesions disseminated in both time and location.
High-dose intravenous corticosteroid therapy, also known
as pulse steroid therapy (PST), is commonly used to treat
a wide range of autoimmune disorders because of its rapid
anti-inflammatory effect and is considered to be standard
therapy for treatment of acute flares of MS [1].
Although many side effects of intravenous steroid in-
fusion are well established in the medical literature,
PST is generally considered to have a good safety pro-
file. Some of the commonly reported adverse effects
following high-dose intravenous steroid infusion are
hyperglycemia, gastrointestinal intolerance, and psychi-
atric manifestations such as euphoria or depression.
Minor transient side effects include facial flushing, fluid
retention, weight gain and parasthesias [1].
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Sinus bradycardia is an uncommon adverse effect fol-
lowing steroid infusion and is very rarely symptomatic.
Herein we report a case of symptomatic sinus bradycardia
in a patient following PST with intravenous methylpred-
nisolone given for treatment of an acute flare of MS.
Case presentation
A 48-year-old Caucasian woman with a history of MS,
smoking, and palpitations was prescribed a 5-day course
of intravenous methylprednisolone (1 gram per day ad-
ministered intravenously) as part of ongoing intensive
therapy for a flare of MS. Her predominant symptoms
were pain and numbness in her legs. One year prior, she
had had a course of PST for similar symptoms. On this
occasion, she noticed that her heart rate felt slow on days
2 and 3 following steroid infusions, but this was transient,
and she felt normal soon afterward. Her documented
heart rate during infusion on those days ranged from 81
to 96 beats per minute (bpm). However, during the infu-
sion on day 4, she noticed that her chest started to feel
heavy, she felt slightly lightheaded, and had difficulty
breathing. She was transferred to the emergency depart-
ment for evaluation of these symptoms. Prior to the infu-
sion, she had only pain and numbness in her legs; the
chest pain and dyspnea started after the infusion. On sub-
sequent questioning, she denied any recent changes in her
list of home medications. She had been taking atenolol for
inappropriate sinus tachycardia (IST) for several years,
and had taken her usual dose of 25mg that morning. Her
usual resting heart ranged from 100 to 120bpm prior to
starting atenolol, and 80 to 100bpm after starting atenolol.
On presentation to the emergency department, her
blood pressure was 124/72mmHg, her pulse was 40bpm,
and her oxygen saturation was 88% on room air. Results
of the physical examination and laboratory tests were
within normal limits. A 12-lead electrocardiogram (ECG)
showed marked sinus bradycardia with a heart rate of
42bpm and normal PR (120msec), QRS (88msec) and
QTc (402msec) intervals (Fig. 1). A prior ECG, done 1 year
earlier, had shown normal sinus rhythm with a rate of
78bpm (Fig. 2). Cardiac biomarkers were normal and pul-
monary embolism was excluded by a computed tomog-
raphy (CT) pulmonary angiogram. She was admitted for
observation on telemetry monitoring with supplemental
oxygen therapy. With time, her oxygen saturation im-
proved to normal on room air.
Telemetry monitoring showed persistence of sinus
bradycardia for 8 hours without atrioventricular block or
ventricular arrhythmias. Our patient denied any further
chest tightness or lightheadedness. The next day, her heart
rate increased to normal sinus rhythm at 80bpm. An echo-
cardiogram was performed and showed normal biventri-
cular size and function without valvular abnormalities.
Her fifth (and final) dose of intravenous methylpredniso-
lone was withheld. As our patient remained asymptomatic
with a normal heart rate, she was discharged from the hos-
pital soon after on her usual home dose of atenolol.
Discussion
Although symptomatic sinus bradycardia following high-
dose steroid infusion has been previously reported, it is
an uncommon occurrence, and relatively underappreci-
ated in the cardiovascular literature. Most of the prior
Fig. 1 Electrocardiogram obtained upon admission showing sinus bradycardia at 42 beats per minute
Kundu and Fitzgibbons Journal of Medical Case Reports  (2015) 9:216 Page 2 of 5
reported cases have been asymptomatic, and all have re-
covered spontaneously over a variable period of time
after stopping the steroid infusion [2–4].
Miura et al. reported sinus bradycardia occurring be-
tween 1 and 82% of children receiving intravenous meth-
ylprednisolone therapy for Kawasaki disease [5]. In a
prospective study in adults by Tvede et al., five patients re-
ceived high-dose intravenous methylprednisolone for
treatment of rheumatoid arthritis [6]. All five patients ex-
perienced sinus bradycardia, although it was symptomatic
in only one patient who reported chest tightness. It was
self-limiting in all the patients, but it took as long as 7 days
for the heart rate to return to normal.
Vasheghani-Farahani et al. conducted a study on 52
patients who were admitted to the hospital for PST for
treatment of an acute flare of MS [7]. The purpose was
to determine the effect of high-dose intravenous methyl-
prednisolone on cardiac rhythms in patients with MS. All
patients underwent continuous cardiac monitoring and a
total of 167 sessions of PST were monitored. Patients with
a history of cardiac disease and those receiving antiarrhyth-
mic drugs or beta blockers were excluded from the study.
The most common cardiac arrhythmia observed was sinus
tachycardia, occurring in 83.8% of patients after steroid
therapy. Sinus bradycardia was observed in 41.9% of the
recorded rhythms after steroid infusion. Sinus bradycardia
was found to be more common in patients who were male,
smokers and those with autonomic disorders such as blad-
der and/or bowel sphincter disturbance [7].
Several hypotheses have been suggested to explain
the pathophysiology of bradycardia following high-dose
steroid infusion, but the exact mechanism still remains
unknown. Both the rates of infusion, and the presence
of underlying heart disease, are thought to increase the
risk of occurrence [8]. Fujimoto et al. monitored ECG
tracings, serum electrolyte levels as well as fractional
excretion of sodium and potassium in 25 patients under-
going treatment with intravenous methylprednisolone for
nephrotic syndrome [9]. Arrhythmias were observed in
four of these patients. Serum potassium levels and frac-
tional excretion of potassium significantly increased from
baseline after PST. This suggests that abnormal cardiac
rhythms may be caused due to sudden changes in potas-
sium flux across the cell membrane [10, 11]. Another pos-
sible mechanism could be alterations in ionized calcium
levels caused by formation of calcium phosphate com-
plexes, which may be induced by the sodium phosphate
contained in some commercially available preparations of
methylprednisolone [12]. However our patient’s serum
calcium and other electrolyte levels were normal on ad-
mission and prior to discharge.
Pudil et al. reported two patients who developed
bradycardia following intravenous methylprednisolone
where technetium-99m pyrophosphate myocardial scan-
ning showed diffusely increased radionuclide accumula-
tion in the myocardium that resolved on follow-up a few
weeks later, suggesting that transient direct damage to
the myocardium as a possible mechanism [13]. Our pa-
tient did not have a pharmacologic perfusion study, but
echocardiography showed normal left ventricular func-
tion, making this explanation less likely. Although sinus
bradycardia has most commonly been associated with
high-dose PST, cases have also been reported following
low-dose methylprednisolone infusion as well as oral
prednisone therapy [14, 15]. Corticosteroids cause so-
dium retention and hypertension due to their intrinsic
Fig. 2 Electrocardiogram done 1-year prior demonstrating normal sinus rhythm at 78 beats per minute
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mineralocorticoid activity. Baroreceptor-mediated reflex
bradycardia in response to hypertension caused by ste-
roids is another potential explanation for bradycardia
seen in patients treated with intravenous steroids [3]. Of
note, our patient had no previous history of hyperten-
sion and her blood pressure level was normal through-
out the course of observation. Finally, it has been
suggested that bradycardia may simply be an idiosyn-
cratic reaction to high-dose steroid infusion in a certain
population of patients [16].
It is debatable whether routine cardiac monitoring is
necessary for all patients receiving high-dose steroid
therapy for treatment of MS, especially as a lot of PST
sessions take place in the outpatient setting. Moreover,
most cases of sinus bradycardia are self-limiting, asymp-
tomatic, and do not require any treatment. White et al.
recommended cardiac monitoring during PST for der-
matologic patients who may have compromised skin
integrity predisposing to electrolyte shifts, and in those
with cardiac and renal disease [17]. It is probably pru-
dent to proceed with a slow rate of steroid infusion and
monitor select patients who have a history of cardiac
disease or those who have experienced adverse effects
following PST in the past. Interestingly, fingolimod, a
recently approved sphingosine-1-phosphate inhibitor for
use in relapsing-remitting MS, also causes sinus brady-
cardia and even second-degree atrioventricular block
[18]. It is recommended that patients receive 6 hours of
continuous ECG and blood pressure monitoring after
the first dose of this oral disease-modifying agent [18].
Although involvement of the autonomic nervous sys-
tem is common in MS, cardiovascular side effects are
not. Autonomic symptoms usually include bowel, blad-
der, or sexual dysfunction. Postural orthostatic tachycar-
dia syndrome (POTS) has been reported in MS, but IST
has not. The latter can be difficult to diagnose as patients
usually suffer from concomitant anxiety and/or pain [19].
Treatment is typically conservative, including beta blockers
and anxiolytics, with electrophysiologic testing reserved for
more severe cases [19]. Our patient has been managed
effectively with the same conservative regimen.
We believe that this case highlights two unique fea-
tures of MS that are not widely appreciated in the adult
cardiovascular literature. One, pulse dose steroid treat-
ment in patients with MS can cause acute asymptomatic
and, more rarely, symptomatic sinus bradycardia. Newer
disease-modifying agents, such as fingolimod, also cause
bradyarrythmias, which can be more frequent and
severe. Patient-specific factors such as active cardiac dis-
ease, smoking status or concomitant medications (that
is, beta blockers) should be considered when administer-
ing these agents [7]. Second, autonomic involvement of
MS can affect the cardiovascular system, and may cause
POTS or IST. Care of patients with MS should be
longitudinal and collaborative, involving primary care,
neurology, cardiology and mental health professionals to
consider all these factors.
Conclusions
In conclusion, our patients’ symptoms of dyspnea, chest
heaviness and lightheadedness were attributed to sinus
bradycardia due to high-dose intravenous methylpred-
nisolone therapy. The majority of prior reported cases
have been asymptomatic and thus, symptomatic sinus
bradycardia remains an extremely rare adverse effect of
PST. It does not warrant any treatment as most cases
are self-limiting and resolve after discontinuing steroid
infusion. Cardiac monitoring is generally not needed if
patients are young and free of active cardiac conditions,
however patient-specific factors, such as the use of con-
comitant medications (that is, beta blockers) and smoking
status should be considered when making this decision.
Finally, chronic symptoms such as palpitations, syncope,
or orthostatic intolerance in MS patients, should raise sus-
picion for cardiovascular effects of MS, which can include
IST or POTS.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
Abbreviations
bpm: beats per minute; CT: computed tomography; ECG: electrocardiogram;
IST: inappropriate sinus tachycardia; MS: multiple sclerosis; PST: pulse steroid
therapy; POTS: postural orthostatic tachycardia syndrome.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AK drafted the manuscript. TF made significant editorial modifications. Both
authors read and approved the final manuscript.
Acknowledgements
Dr. Fitzgibbons’ research is supported by a Fellow-to-Faculty Transition
Award from the National Affiliate of the American Heart Association (number
12FTF1126090) and the Harold S. Geneen Charitable Trust.
Author details
1Department of Medicine, University of Massachusetts Medical School, 55
Lake Avenue North, Worcester, MA 01655, USA. 2Department of Medicine,
Cardiovascular Division, University of Massachusetts Medical School, 55 Lake
Avenue North, Worcester, MA 01655, USA.
Received: 30 January 2015 Accepted: 31 August 2015
References
1. Lyons PR, Newman PK, Saunders M. Methylprednisolone therapy in multiple
sclerosis: a profile of adverse effects. J Neurol Neurosurg Psychiatry.
1988;51:285–7.
2. van der Gugten A, Bierings M, Frenkel J. Glucocorticoid-associated
bradycardia. J Pediatr Hematol Oncol. 2008;30:172–5.
Kundu and Fitzgibbons Journal of Medical Case Reports  (2015) 9:216 Page 4 of 5
3. Akikusa JD, Feldman BM, Gross GJ, Silverman ED, Schneider R. Sinus
bradycardia after intravenous pulse methylprednisolone. Pediatrics.
2007;119:e778–82.
4. Hsu DT. Steroids and bradycardia: how slow can you go? J Pediatr Hematol
Oncol. 2008;30:119–20.
5. Miura M, Ohki H, Yoshiba S, Ueda H, Sugaya A, Satoh M, et al. Adverse
effects of methylprednisolone pulse therapy in refractory Kawasaki disease.
Arch Dis Child. 2005;90:1096–7.
6. Tvede N, Nielsen LP, Andersen V. Bradycardia after high-dose intravenous
methylprednisolone therapy. Scand J Rheumatol. 1986;15:302–4.
7. Vasheghani-Farahani A, Sahraian MA, Darabi L, Aghsaie A, Minagar A.
Incidence of various cardiac arrhythmias and conduction disturbances due
to high dose intravenous methylprednisolone in patients with multiple
sclerosis. J Neurol Sci. 2011;309:75–8.
8. Guillén EL, Ruíz AM, Bugallo JB. Hypotension, bradycardia, and asystole after
high-dose intravenous methylprednisolone in a monitored patient. Am J
Kidney Dis. 1998;32, E4.
9. Fujimoto S, Kondoh H, Yamamoto Y, Hisanaga S, Tanaka K. Holter
electrocardiogram monitoring in nephrotic patients during
methylprednisolone pulse therapy. Am J Nephrol. 1990;10:231–6.
10. Parham WA, Mehdirad AA, Biermann KM, Fredman CS. Hyperkalemia
revisited. Texas Heart Inst J. 2006;33:40–7.
11. Dananberg J. Electrolyte abnormalities affecting the heart. In: Schwartz GR,
editor. Principles and practice of emergency medicine. 4th ed. Baltimore:
Williams & Wilkins; 1999. p. 425–7.
12. Moses RE, McCormick A, Nickey W. Fatal arrhythmia after pulse
methylprednisolone therapy. Ann Intern Med. 1981;95:781–2.
13. Pudil R, Hrncir Z. Severe bradycardia after a methylprednisolone minipulse
treatment. Arch Intern Med. 2001;161:1778–9.
14. Darling HS, Marwah V, Rajput AK, Varma PP, Singh KK. Low dose
methylprednisolone induced bradycardia. J Assoc Physicians India. 2013;61:920–2.
15. Al Shibli A, Al Attrach I, Hamdan MA. Bradycardia following oral
corticosteroid use: case report and literature review. Arab J Nephrol
Transplant. 2012;5:47–9.
16. Lucas KG, Howrie DL, Phebus CK. Cardiorespiratory decompensation
following methylprednisolone administration. Pediatr Hematol Oncol.
1993;10:249–55.
17. White KP, Driscoll MS, Rothe MJ, Grant-Kels JM. Severe adverse
cardiovascular effects of pulse steroid therapy: is continuous cardiac
monitoring necessary? J Am Acad Dermatol. 1994;30:768–73.
18. Schurmann P, Basra S, Awar OG, Aguilar D, Basant A, Dragan E, et al.
Abnormal rhythms in patients without known cardiac disease after a first
dose of fingolimod. Mult Scler Relat Disord. 2014;3:408–12.
19. Olshansky B, Sullivan RM. Inappropriate sinus tachycardia. J Am Coll Cardiol.
2013;61:793–801.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kundu and Fitzgibbons Journal of Medical Case Reports  (2015) 9:216 Page 5 of 5
